Related Experiment Video

Updated: Jul 18, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness

Johan Bussink1, Johannes H A M Kaanders, Albert J van der Kogel

  • 1Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. j.bussink@rther.umcn.nl

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|December 5, 2006
PubMed

Insights

Targeted therapies blocking EGFR and VEGFR show promise in improving radiotherapy. Understanding their effects on tumor microenvironments is key to optimizing cancer treatment combinations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Tumor microregional dynamics, including hypoxia and proliferation, influence aggressiveness and treatment resistance.
  • Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors are biological targeted drugs with potential to enhance radiotherapy.
  • Current understanding of the mechanistic basis for combined therapies and microregional tumor phenotype under targeted blockade is limited.

Purpose of the Study:

  • To investigate if EGFR or VEGFR blockade modulates microregional tumor phenotypes.
  • To determine how downstream signaling pathway effects relate to these phenotypic changes.
  • To assess the impact of microregionally induced changes on tumor responsiveness to ionizing radiation.

Main Methods:

  • Analysis of microregional tumor cell hypoxia and proliferation dynamics.
  • Evaluation of downstream signaling pathway alterations following EGFR and VEGFR inhibition.
  • Assessment of tumor response to ionizing radiation in combination with targeted therapies.

Main Results:

  • (Not explicitly stated in the abstract, but implied focus on understanding the mechanisms)

Conclusions:

  • Further research is needed to elucidate the interactions between targeted therapies and tumor microenvironments.
  • Understanding these mechanisms will optimize therapeutic combinations and treatment strategies.
  • This knowledge can guide the development of novel biological-based treatment approaches.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...